ClinicalTrials.gg
CompletedNCT02588677Updated Sep 29, 2023

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

A Phase 2/3 interventional study of Masitinib (4.5) and Riluzole in Amyotrophic Lateral Sclerosis (ALS), sponsored by AB Science. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by AB Science · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2016, 9 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2018.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.

Enrollment
13th of 51
394 · median 227
Started
2013
with 1 other
Phase 2/3
2 of 56
none open now
Registered
15th of 56
by date
Lead sponsor
2 of 56
AB Science

Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 13th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2013, is one of 2 in phase 2/3, and was the 15th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

Read the detailed description

Masitinib is novel tyrosine kinase inhibitor that targets microglia and mast cells through inhibiting a limited number of kinases. Masitinib blocks microglia proliferation and activation, and mast cell-mediated degranulation, the release of cytotoxic substances that might further damage the motor nerves.

There are two distinct populations of ALS patients: population of "Normal progressors" and population of "Faster progressors". Targeted population for primary analysis is population of "Normal progressors".

"Normal progressors" are ALS patients whose progression of ALSFRS-R score before randomization is less than 1.1 point per month.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis (ALS) - masitinib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Main inclusion criteria:

  1. Familial or sporadic ALS
  2. Patient diagnosed with probable of definite ALS
  3. Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening

Exclusion criteria

Exclusion Criteria:

  1. Patient who underwent tracheostomy and/or gastrostomy
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
394 participants (actual)

Study arms

  • Experimental
    Masitinib (3.0) & Riluzole

    masitinib 3 mg/kg/day + riluzole

    Drug: Riluzole · Drug: Masitinib (3.0)

  • Experimental
    Masitinib (4.5) & Riluzole

    masitinib 4.5 mg/kg/day (2) + riluzole

    Drug: Masitinib (4.5) · Drug: Riluzole

  • Placebo comparator
    Placebo & Riluzole

    Matched placebo

    Drug: Riluzole · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised

    The amyotrophic lateral sclerosis functional rating scale (ALSFRS), which is a Validated instrument that assesses the functional status and the disease progression in patients with amyotrophic lateral sclerosis (ALS)

    Time frame: From baseline to week 48

Secondary outcomes

  1. Change of Forced Vital Capacity (FVC)

    Forced vital capacity (FVC) measures the volume of air expelled from the lungs during a quick, forceful breath.

    Time frame: From baseline to week 48

  2. Progression Free Survival

    Progression Free Survival is defined as the time from the randomization date until the earliest date for a decline of more than 9-points in ALSFRS-R score

    Time frame: Time from the randomization date until the earliest date for a decline of more than 9-points in ALSFRS-R score, asssesd over a maximum of 60 months

  3. Overall Survival

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause.

    Time frame: Time from the randomization date until death, asssesd over a maximum of 60 months

07

Study locations

1 site
  • Hospital Carlos III
    Madrid, 28029, Spain
08

References and documents

Publications

  • Mora JS, Bradley WG, Chaverri D, Hernandez-Barral M, Mascias J, Gamez J, Gargiulo-Monachelli GM, Moussy A, Mansfield CD, Hermine O, Ludolph AC. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2021 Jul 19;14:17562864211030365. doi: 10.1177/17562864211030365. eCollection 2021. PubMed 34457038 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Dec 2016 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2015
First posted
Oct 28, 2015
Start
Apr 2013
Primary completionActual
Dec 5, 2016
CompletionActual
Mar 2018
Results delay requested
Dec 12, 2018
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02588677
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Apr 2013
Primary completion
Dec 5, 2016
Completion
Mar 2018
Last update
Sep 29, 2023

Study contacts

Jesus S Mora, MD
principal investigator · Unidad de ELA, Hospital San Rafael, c/ Serrano, 199, 28016 Madrid, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion